Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence
Posted inClinical Updates Nephrology Specialties

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone's efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing future directions for mineralocorticoid receptor antagonism in this population.
Intermittent Fasting vs Low-Calorie Diet in Managing Metabolic-Associated Fatty Liver Disease: Comparative Effects on Inflammation, Lipids, Glycemic Control, and Liver Fibrosis
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Intermittent Fasting vs Low-Calorie Diet in Managing Metabolic-Associated Fatty Liver Disease: Comparative Effects on Inflammation, Lipids, Glycemic Control, and Liver Fibrosis

This RCT compares 16:8 intermittent fasting and low-calorie diets in MAFLD patients, revealing both improve liver enzymes and anthropometrics, but low-calorie diet shows superior reduction in liver steatosis, fibrosis, and triglycerides.
Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial
Posted inClinical Updates Gastroenterology Specialties

Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite primary endpoint statistical thresholds not being met by total Mayo scores.
Dietary Approaches to Stop Hypertension (DASH) for the Primary and Secondary Prevention of Cardiovascular Diseases: A Systematic Review of Randomised Controlled Trials
Posted inCardiology Clinical Updates Family Medicine & Nutrition news Specialties

Dietary Approaches to Stop Hypertension (DASH) for the Primary and Secondary Prevention of Cardiovascular Diseases: A Systematic Review of Randomised Controlled Trials

This review evaluates the DASH diet's impact on major cardiovascular outcomes, synthesizing evidence from RCTs and highlighting its benefits on blood pressure and lipid profiles amid gaps in long-term clinical outcome data.
Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial
Posted inClinical Updates Family Medicine & Nutrition Gastroenterology news Specialties

Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial

The CARIBS trial shows that both low FODMAP plus traditional dietary advice and a low-carbohydrate diet outperform optimized pharmacologic treatment in reducing IBS symptom severity after 4 weeks, highlighting the importance of dietary interventions as first-line therapy.
Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study
Posted inClinical Updates news Respiratory Specialties

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study

A national French study reveals that cold agglutinin syndrome (CAS) develops about 10 days after Mycoplasma pneumoniae infection onset, often requiring ICU care and transfusions, with a generally favorable prognosis despite frequent venous thromboembolism and no clear benefit from glucocorticoid treatment.